Cantor Fitzgerald Predicts ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn $0.05 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

ESPR has been the topic of several other reports. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Trading Down 2.7 %

NASDAQ:ESPR opened at $2.15 on Wednesday. The company’s 50 day moving average is $2.46 and its two-hundred day moving average is $2.18. The company has a market cap of $423.64 million, a PE ratio of -3.36 and a beta of 1.03. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The firm had revenue of $51.63 million during the quarter, compared to analysts’ expectations of $55.44 million. During the same period last year, the firm earned ($0.37) earnings per share.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently made changes to their positions in the company. Traphagen Investment Advisors LLC purchased a new stake in Esperion Therapeutics during the third quarter worth $27,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at about $28,000. Versor Investments LP purchased a new position in shares of Esperion Therapeutics in the 3rd quarter valued at about $44,000. American Century Companies Inc. acquired a new position in Esperion Therapeutics in the 2nd quarter worth about $50,000. Finally, SJS Investment Consulting Inc. acquired a new position in Esperion Therapeutics in the 4th quarter worth about $55,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.